REG - Cambridge Cognition - Director/PDMR Share Purchases

Cambridge Cognition HoldingsAnnouncement

30/01/2024 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240130:nRSd4188Ba&default-theme=true

RNS Number : 4188B  Cambridge Cognition Holdings PLC  30 January 2024

30 January 2024

Cambridge Cognition Holdings Plc

("Cambridge Cognition", the "Company" or the "Group")

Director/PDMR Share Purchases

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets
digital solutions to assess brain health, was informed on 30 January 2024 that
Nick Rodgers, Non-Executive Director of the Company, purchased 20,000 ordinary
shares of 0.01 pence each ("Ordinary Shares") in the Company at a price of
52.449 pence per share.

Following this transaction, Nick Rodgers holds an interest in 20,000 Ordinary
Shares, representing approximately 0.06% of the Company's issued share
capital.

Further information on the purchases is contained in the disclosure tables
below.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Nick Rodgers
 2    Reason for the notification
 a)   Position/status                                              Non-Executive Director
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Cambridge Cognition Holdings Plc
 b)   LEI                                                          213800SZKDIN122EPA96
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary shares of 0.01p each

      Identification code

                                                                   GB00B8DV9647
 b)   Nature of the transaction                                    Purchase of Shares
 c)   Price(s) and volume(s)                                         Price(s)    Volume(s)
                                                                   52.449 pence  20,000

 
 d)   Aggregated information                                       n/a

      - Aggregated volume

      - Price
 e)   Date of the transaction                                      30 January 2024
 f)   Place of the transaction                                     London Stock Exchange

 

d)

Aggregated information

- Aggregated volume

- Price

n/a

e)

Date of the transaction

30 January 2024

f)

Place of the transaction

London Stock Exchange

 

 

For further information, please contact:

 Cambridge Cognition Holdings Plc                        Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer                  press@camcog.com (mailto:press@camcog.com)

 Stephen Symonds, Chief Financial Officer

 Panmure Gordon (UK) Limited (NOMAD and Joint Broker)    Tel: 020 7886 2500

 Freddy Crossley / Emma Earl                             (Corporate Finance)

 Rupert Dearden                                          (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                  Tel: 020 3903 7715

 David Poutney / James Serjeant

 Hudson Sandler (Financial PR and IR)                    Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus                          cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHWPUBGGUPCGQU